Abingworth, a UK-based life sciences investor backed by Carlyle, is raising up to $1.5bn for clinical trials and royalty partnerships with pharmaceutical companies. Recent collaborations with Gilead Sciences and Teva demonstrate the fund’s focus on funding late-stage trials for promising drugs. Abingworth’s successful track record in phase-three trials, coupled with the current demand for new medicines, positions the fund as an attractive option for pharma companies seeking to maximize drug development opportunities.
Full Article
François Bayrou appointed French prime minister
President Emmanuel Macron has appointed centrist politician François Bayrou as the new prime minister in an effort to stabilize political turmoil in France. Bayrou, a three-time presidential candidate, has a market-oriented economic view and supports social justice measures. His appointment has faced criticism from Macron's opponents, who argue that he lacks democratic legitimacy and must engage in dialogue with all parties. The uncertainty in French politics has caused concern among businesses and investors. Bayrou's ability...
Read more